UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report Filed Pursuant to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report
(Date
of earliest event reported): December 30, 2010
Repros
Therapeutics Inc.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-15281
|
76-0233274
|
|
(State
or other jurisdiction of incorporation or organization)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
|
2408
Timberloch Place, Suite B-7
The
Woodlands, Texas 77380
(Address
of principal
executive
offices
and
zip code)
|
||
|
(281)
719-3400
(Registrant’s
telephone number, including area code)
|
||
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2 below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
Repros
Therapeutics Inc. (the “Company”) has decided to reinstitute its at-the-market
offering of its common stock, pursuant to the Equity Distribution Agreement
dated February 12, 2010 between the Company and Ladenburg Thalmann & Co.
Inc. Cumulative through December 30, 2010, the Company has sold
2,448,572 shares of its common stock in its at-the-market offering, at a
weighted average share price of $2.77, for proceeds of approximately $6.4
million, net of expenses. Pursuant
to General Instruction I.B.6. of Form S-3, the Company may not sell more than
one-third of the aggregate market value of its common stock held by
non-affiliates during a period of 12 calendar months immediately prior to, and
including, the date of such sale of such common stock. The Company may from time
to time elect to cease or restart its at-the-market offering without the filing
of a Form 8-K.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Company has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| Repros Therapeutics Inc. | |||
| Date: December 30, 2010 | |||
|
|
By:
|
/s/ Joseph S. Podolski | |
| Joseph S. Podolski | |||
| President and Chief Executive Officer | |||